Alerts

We are advising that Movectro (cladribine) has been withdrawn from supply in Australia due to commercial reasons.

We are reviewing the safety of the Pneumovax 23 vaccine due to reports of severe local reactions and have updated our revaccination recommendations.

On 26 January 2011, the US Food and Drug Administration (FDA) announced a safety communication to warn about an association between breast implants and anaplastic large cell lymphoma. The risk of a patient developing this type of lymphoma is very low.

We are recalling Thelin (sitaxentan) worldwide due to serious liver risks. Consult your doctor if you have concerns.

Seasonal flu vaccine: Response to the West Australian (Stokes) Review

Do not use So Hard for Men tablets, Shaguar tablets, and Pulse8 for Women capsules as they contain undeclared tadalafil and are not approved. Consult your doctor if you have concerns.

Weight loss drug Sibutramine (Reductil) withdrawn in Australia due to heart risks.

The TGA is aware that the French authorities have now released an updated statement in regard to the testing of the PIP implants:

We are analysing the safety of the Panvax H1N1 vaccine following reports of febrile convulsions in children.

We are investigating febrile reactions in young children following the 2010 flu vaccine and have paused its use for kids under 5 in Western Australia.

The Therapeutic Goods Administration (TGA) advises that Octapharma Australia Pty Ltd has agreed to a precautionary voluntary recall of all batches of Octagam intravenous immunoglobulin solutions from the Australian market.

Testing on Australian Poly Implant Prothèse (PIP) samples of implants has been undertaken by TGA